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in eukaryotes, pyridoxal kinase (pDXK) acts in vitamin B6 salvage pathway to produce pyridoxal 
5′-phosphate (pLp), the active form of the vitamin, which is implicated in numerous crucial metabolic 
reactions. in Drosophila, mutations in the dPdxk gene cause chromosome aberrations (cABs) and 
increase glucose content in larval hemolymph. Both phenotypes are rescued by the expression of the 
wild type human pDXK counterpart. Here we expressed, in dPdxk1 mutant flies, four PDXK human 
variants: three (D87H, V128I and H246Q) listed in databases, and one (A243G) found in a genetic 
screening in patients with diabetes. Differently from human wild type PDXK, none of the variants was 
able to completely rescue cABs and glucose content elicited by dPdxk1 mutation. Biochemical analysis 
of D87H, V128I, H246Q and A243G proteins revealed reduced catalytic activity and/or reduced affinity 
for pLp precursors which justify this behavior. Although these variants are rare in population and carried 
in heterozygous condition, our findings suggest that in certain metabolic contexts and diseases in 
which pLp levels are reduced, the presence of these pDXK variants could threaten genome integrity and 
increase cancer risk.
Differently from bacteria and plants which synthesize ex novo the active form of vitamin B6, pyridoxal 5′ phos-
phate (PLP), in other organisms PLP production relies on the salvaging activity of two enzymes: pyridoxal 
5′-phosphate kinase (PDXK) and pyridoxine 5′-phosphate oxidase (PNPO). PDXK converts PLP precursors such 
as pyridoxal (PL), pyridoxamine (PM) and pyridoxine (PN) taken from food into PLP, PMP and PNP, respec-
tively. PNPO catalyzes the oxidation of PMP and PNP into PLP1. PLP performs many functions by working as 
coenzyme for a wide number of enzymes which control amino acid, lipid and carbohydrate metabolism. In addi-
tion, it takes part to the synthesis and/or catabolism of certain neurotransmitters2,3 and behaves as antioxidant 
molecule by counteracting genotoxic molecules such as oxygen reactive species (ROS) and Advanced Glycation 
End products (AGEs)4–6. Furthermore, B6 levels of cells can also modulate the capability to respond to steroid 
hormones7. As a consequence of such a wide spectrum of functions, disorders of vitamin B6 metabolism have 
been associated to different human pathologies such as epilepsy, diabetes, autism, schizophrenia, Alzheimer, 
Parkinson, Down’s syndrome and cancer8,9. Many reports based on either in vitro or in vivo observations support 
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the hypothesis that vitamin B6 would promote antiproliferative effects on cancer cells10. In addition, epidemio-
logical studies reported that elevated circulating amounts of B6 vitamers as well as an intense consumption of 
vitamin B6-containing food correlate with a reduced incidence of several distinct tumors including colorectal 
cancer11. Furthermore, it has been reported that high expression levels of PDXK positively correlate with survival 
of non-small cell lung cancer (NSCLC) patients12. Although many studies converge towards a protective role of B6 
in cancer, underlying molecular mechanisms are not completely understood. Recently, several lines of evidence 
are accumulating which pinpoint to DNA damage as a possible link between metabolism and cancer. In particu-
lar, it has been proposed that under metabolic stress conditions or in the case of reduced availability of necessary 
nutrients some cellular processes such as DNA acetylation/methylation, synthesis of DNA precursors and ROS 
production can be altered causing DNA damage which can drive cells toward cancer13. Vitamin B6 is an antioxi-
dant molecule and plays an important role in one-carbon metabolism, a set of reactions involved in the transfer 
of one-carbon groups which are at the basis of amino acid and nucleotide metabolism. As a consequence, vitamin 
B6 could represent a possible candidate to mediate the cross talk between metabolism and DNA damage. In line 
with this hypothesis, using Drosophila as model system, we demonstrated that mutations in the dPdxk gene cause 
chromosome aberrations (CABs) rescued by PLP supplementation. The same effect is produced by treating wild 
type flies with PLP analogues such as 4-deoxypyridoxine (4-DP) or inhibitors of PLP-dependent enzymes like 
cycloserine and penicyllamine14. Besides eliciting CAB formation, dPdxk1 mutations increase the glucose content 
in larval hemolymph. We demonstrated that in dPdxk1 mutants hyperglycemia and CABs are interconnected 
by a cause-effect relationship, in which high glucose is largely responsible for CABs. High glucose triggers AGE 
formation, which through ROS production leads to CABs14. The role of PDXK in chromosome integrity mainte-
nance has also been demonstrated in yeast showing that mutations in the BUD16 gene, the PDXK ortholog, cause 
gross chromosome rearrangements largely mediated by altered DNA synthesis15. The impact of low PLP levels on 
genome integrity has also been tested on human cells. HeLa cells deprived of PLP by RNA interference directed 
against the PDXK gene showed chromosome aberrations (38.5% vs 2.0% in mock cells). Moreover, the treatment 
of mock HeLa cells with 4-DP causes chromosome aberrations14, p53 binding protein 1 (53BP1) and γ-H2AX 
repair foci accumulation15. Confirming the evolutionarily conserved role of PDXK gene in DNA integrity main-
tenance, we have previously demonstrated that the expression in Drosophila of the wild type human PDXK gene 
in a dPdxk1 background fully rescues CABs14.
In this work, we investigated whether human PDXK variants present in the population can impact on DNA 
integrity and be considered predictive of an increased cancer risk. For this purpose, we expressed four human 
PDXK variants (carrying missense mutations) into dPdxk1 mutant flies and tested them for CABs showing that 
none of them was able to completely rescue the CAB phenotype. Biochemical analysis of all these variants reve-
led a compromised catalytic activity and/or affinity for their substrates, which explained their “loss of function” 
behavior. These results translated to humans suggest that mutations in PDXK gene can impact on genome integ-
rity and predispose to cancer.
Results
Genetic and biochemical basis of the study. We previously demonstrated that mutations in 
the Drosophila dPdxk gene cause lethality at the third larval instar and formation of CABs which can be rescued 
by PLP supplementation14. siRNAs directed against human PDXK gene induce the formation of CABs in fibro-
blasts and HeLa cells14 and, in addition, the PLP analogue 4-deoxypyridoxine (4-DP) increases the formation of 
53BP1 repair foci in HeLa cells15. These findings prompted us to speculate that humans carrying mutations in the 
PDXK encoding gene could have an increased propensity to accumulate chromosome aberrations and a conse-
quent increased risk to develop malignances. To evaluate this hypothesis, we decided to express human PDXK 
loss-of-function variants in flies homozygous for the dPdxk1 mutation14 and test them for their effects on CABs. 
The rationale of this strategy comes from our previous data14 showing that a wild type copy of the human PDXK 
gene can rescue CABs when expressed in dPdxk1 mutants.
We analyzed four human PDXK variants: Asp87His (D87H), Val128Ile (V128I), His246Gln (H246Q) and 
Ala243Gly (A243G). The first three have been picked up from the Exome variant server (Exome variant server, 
http://evs.gs.washington.edu/EVS/) which contains numerous human PDXK variants not yet associated to any 
disease. The variants have been chosen considering their putative damaging effects predicted in silico by the 
PolyPhen-2 software and their evolutionarily conservation of the mutated residues in Drosophila. In particular 
D87H displays the highest damaging score (1.0) and concerns a conserved position in Drosophila and human 
PDXKs; V128I and H246Q carry mutations in invariant positions (http://www.flyrnai.org/cgi-bin/DRSC_ort-
hologs.pl) and in addition display high damaging scores (0.99 and 0.98 respectively) (Fig. 1A,C). These variants are 
very rare in the population (their frequency ranging from 2.84e-5 to 7.97e-6; https://gnomad.broadinstitute.org/) 
and are carried in heterozygous state.
A243G (Fig. 1A,C) is absent in major databases, displays a damaging score of 0.72 (Supplementary Fig. S1) 
and has been found in a genetic screening in patients with gestational diabetes. The rationale for the aforemen-
tioned investigation was the previously reported beneficial effect of vitamin B6 on gestational diabetes and its 
possible effect on insulin secretion in a murine model16–18.
None of the chosen variants concerns amino acid residues that are directly involved in substrate binding or 
catalysis; however, these residues are located in, or connected to, pivotal structural regions of the enzyme. PDXK 
is a dimer of two identical monomers. Each subunit is made by 9 α-helices and 11 β-strands that form a central 
β-sheet flanked by helices on both sides. Asp87 is placed on the C-terminal end of an active site loop connecting 
α3 helix and strand β4, which plays a crucial role in substrate binding. Tyr84, which is part of this loop, directly 
interacts with the B6 vitamer substrate stacking to its pyridine ring (Supplementary Fig. S2A) (PDB code: 3KEU 
and Musayev et al.19). The Val128 residue is part of another active site loop, located between strands β6 and β7 
(Supplementary Fig. S2B), that closes on the active site as ATP binds to the enzyme. This loop, which is referred 
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to as a flap in pyridoxal kinases, provides hydrogen bond interactions to the ATP β- and γ-phosphates (Tyr127, 
adjacent to Val128, binds to the γ-phosphate of ATP), and is believed to sequester ATP for catalysis, preventing 
its unproductive hydrolysis in the absence of a bound B6 vitamer20–22. Thus, variants of residues V128 and D87, 
which are spatially quite close to each other, are expected to affect substrate binding. On the other hand, A243 and 
H246, which are also close together, are located at the C-terminal end of helix α7, formed by residues 231–234, on 
the opposite side of the monomer with respect to the active site and therefore at a distance from it (Supplementary 
Fig. S2B). However, the N-terminus of this helix, which is positioned at the active site, contributes with its posi-
tive charge to binding of the PLP product of the reaction catalyzed by PDXK, stabilizing its phosphate moiety23. 
A243G and H246Q variants are predicted to have milder effects than V128I and D87H on the enzyme catalytic 
properties.
Human pDXK variants fail to rescue cABs in dPdxk1 mutant flies. By site-directed mutagenesis, we 
generated four constructs of human HA-tagged PDXK cDNA, each containing a variant, and introduced them in 
flies by germline mediated transformation. We validated the expression of these constructs by western blot anal-
ysis using an anti HA antibody (Fig 1B and Supplementary Fig. S3). By performing suitable crosses (described in 
Figure 1. Human PDXK variants examined in this study. (A) Table listing human PDXK variants, studied in 
this work, present in Exome variant server (D87H, V128I, H246Q) or found at genetic screening (A243). (B) 
Western blot showing protein expression of PDXK human variants in brains from dPdxk1 Drosophila mutants. 
An antibody anti-HA was used to detect PDXK proteins. α-tubulin served as loading control (LC). (C) Clustal 
Omega pairwise sequence alignment of Drosophila melanogaster Pdxk (NP_996031.1) with that of Homo 
sapiens (NP_003672.1). Dash indicates the identical residues, colon indicates the conserved residues. Mutated 
residues carried by variants examined in this study are boxed.
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Methods), we introduced these variants in dPdxk1 mutant flies and tested them for CABs in DAPI stained brain 
preparations from third instar larvae. As reported in Fig. 2A,B, the D87H, V128I, H246Q and A243G variants 
were unable to completely rescue CABs unless the larvae were reared in a medium containing PLP (1 mM). The 
expression of either wild type or variant PDXK forms in a dPdxk1/+ background did not produce CABs, allowing 
us to exclude any dominant negative effect (Fig. 1B).
Taken together, these findings suggest that all tested variants behave as loss of function alleles which impact 
on genome integrity.
pDXK human variants expressed in dPdxk1 flies impact on glucose metabolism. Mutations 
in the dPdxk gene, besides promoting CAB formation, increase glucose content in the hemolymph, generat-
ing “diabetic” flies14. We have previously proposed a model in which high glucose levels in the hemolymph 
resulting from the dPdxk1 mutation is largely responsible for CABs because it induces an overproduction of 
Advanced Glycation End products (AGEs). In turn, AGEs produce oxygen reactive species (ROS) that are well 
recognized for damaging DNA and leading to CAB formation14. To verify whether the expression of D87H, 
V128I, H246Q and A243G variants influenced glucose homeostasis, we tested glucose levels and found that 
none of the variants was able to significantly reduce hyperglycemia caused by dPdxk1 mutation, which was 
instead decreased by PLP treatment (Fig. 3A). In addition, immunostaining experiments showed that the 
dPdxk1 cells expressing D87H, V128I, H246Q and A243G variants accumulated AGEs, which were further 
increased by 1% glucose treatment (Fig. 3B,C), according to the hypothesis that AGEs are largely responsible 
for CABs in PLP depleted cells9,14,24,25.
H246Q, D87H, V128I and A243G variants respond differently to PLP precursors. To investigate 
why PDXK variants failed to rescue CABs in the dPdxk1 background, we examined the effect of PLP precursors 
(PL, PM and PN) on CAB frequency in brains from larvae expressing D87H, V128I, H246Q and A243G variants. 
As reported in Fig. 4A–D we tested PLP precursors at two different concentrations (0.5 and 1 mM) and we found 
that each variant behaved differently. In brains expressing D87H, PL treatment did not rescue CABs. A feeble 
rescue effect was observed with PM (1 mM). In contrast, PN reduced significantly CAB frequency but only at 
1 mM concentration. In brains expressing V128I, neither at 0.5 nor at 1 mM concentration PL was able to rescue 
CAB frequency, whereas both PM and PN rescued CABs at 1 mM concentration. In H246Q expressing cells PL 
and PM reduced CAB frequency only at 1 mM concentration, whereas PN reduced CAB frequency also at 0.5 mM 
concentration. In A243G expressing neuroblasts all precursors rescued CABs but only at 1 mM concentration. 
Note that PLP treatment rescued CABs at both concentrations in all tested variants.
These data suggest that the replacement of H246, V128, D87 and A243 amino acids with those found in the 
respective variants can impact on PDXK functionality by altering in different ways its capability to phosphorylate 
the substrates.
Biochemical characterization of H246Q, D87H, V128I and A243G variants. To better understand 
why the four PDXK mutant proteins responded differently to PLP precursors, variant PDXK enzyme forms 
were recombinantly expressed in Escherichia coli, purified to homogeneity and characterized with respect to 
Figure 2. Human PDXK variants expressed in dPdxk1 flies do not rescue CABs. (A) Examples of chromosome 
aberrations in neuroblasts from larvae expressing PDXK variants in dPdxk1 background. A1 wild type 
metaphase; A2 and A6 autosomal chromatid deletion (arrows); A4 and A5 isochromatid deletion (arrowed); 
A3 isochromatid deletion at the level of centromere (arrows). Scale Bar 5 μm. (B) Quantification of CABs. 
Each bar represents the mean value ± SD obtained by scoring at least 5 brains (∼800 cells) for genotype. 
*,**,***Significantly different in the Student’s t test with p < 0.05, 0.01 and 0.001 respectively. (dPdxk1 with 
respect to wt and to dPdxk1 + PLP is <0.001, not reported in the graph).
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their catalytic properties with PL, PN and PM as substrates. As shown in Table 1, all the four mutant enzymes 
showed altered kinetic parameters. In particular, the D87H mutation strongly increased KM for PL, and to a 
lesser extent also increased KM for PN and PM, leaving KM for ATP and kcat almost unaltered. These observations 
are well-matched with the location of the Asp87 residue on an active site loop that plays a crucial role in the B6 
vitamer substrate binding, and in particular with the direct interaction between the adjacent Tyr84 with the B6 
vitamer pyridine ring (Supplementary Fig. S2A). The V128I mutation drastically increased KM for PL and KM for 
ATP with this vitamer, whereas it did not affect kcat. This was expected, considering the role of the active site loop 
containing Val128 in substrate binding and specifically in the interaction with ATP (Supplementary Fig. S2B). KM 
for PN and PM were also increased, although with these vitamers KM for ATP and kcat were unaltered. This latter 
observation is difficult to explain on the basis of the available observed results; however, it suggests that binding of 
B6 vitamers different from PL may affect the modality of ATP binding by the loop containing Val128. The H246Q 
mutation somewhat reduced the affinity for ATP when using PL as substrate and the affinity for PM, while it did 
not affect KM for PL and PN. In addition, it had the effect to halve kcat with PL. Finally, A243G mutation displayed 
a behavior very similar to that showed by the H246Q mutation. Given the distance of Ala243 and His246 from the 
active site, the observed alteration of the kinetic parameters, although relatively mild, testifies that the mutation 
of these residues is somehow transmitted to the active site of the enzyme.
Taken together, these findings indicate that the specific changes introduced in the four examined variants 
reduce the PDXK functionality threatening genome integrity and impairing glucose homeostasis.
Figure 3. Human PDXK variants expressed in dPdxk1 flies do not rescue hyperglycemia. (A) Glucose content 
in hemolymph from larvae expressing either wild type or PDXK variants, reared on standard medium with or 
without PLP (1 mM) supplementation. Columns are the means of 5 independent sample measurements ± SD 
(each sample = hemolymph extracted from 20 larvae). **,***Significantly different in the Student’s t test with 
p < 0.01 and <0.001 respectively. (B) Examples of neuroblasts from untreated and 1% glucose treated brains 
expressing wt and D87H PDXK stained with an anti-human AGE antibody. Scale Bar 5 μm. G = glucose (C) 
Frequencies of AGE-positive cells in brains untreated (un) and exposed to 1% glucose (G). Bars in the graph 
represent the mean frequencies of AGE-positive cells (±SD) in three independent experiments by scoring at 
least 1000 cells in 4 brains. ***Significantly different in the Student’s t test with p < 0.001.
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Discussion
Limitations imposed by human subject research can be overcome by generating models of human diseases in 
experimental organisms. Due to widely conserved pathways which govern metabolism, Drosophila has been 
retained a precious organism for the study of metabolic human genetic diseases, either as a means of validating 
Figure 4. Effect of PLP precursors (PL, PM and PN) on CAB frequency in brains from larvae expressing D87H 
(A), V128I (B), H246Q (C) and A243G (D) variants. Each bar represents the mean value ± SD obtained by 
scoring at least 8 brains (∼1000 cells) for genotype. *,**,***Significantly different in the Student’s t test with 
p < 0.05, 0.01 and 0.001 respectively.
PDXK
PL as substrate PN as substrate PM as substrate
aKM PL (µM) aKM ATP (µM) bkcat (min−1) aKM PN (µM) aKM ATP (µM) bkcat (min−1) aKM PM (µM) aKMATP (µM) bkcat (min−1)
WT 189 ± 27 407 ± 65 58 ± 3 7.0 ± 0.9 104 ± 24 19 ± 2 5.0 ± 0.5 46.2 ± 8.2 6.9 ± 0.2
D87H 2090 ± 173 377 ± 48 40 ± 1 34.1 ± 0.4 125 ± 16 21 ± 3 26.5 ± 6.3 55.3 ± 9.1 7.2 ± 0.4
V128I 3839 ± 507 3096 ± 555 67 ± 5 24.8 ± 0.2 113 ± 6 20 ± 4 51.5 ± 6.3 56.3 ± 7.2 8.5 ± 0.2
H246Q 141 ± 10 901 ± 164 35 ± 1 11.5 ± 2.1 126 ± 1 17 ± 4 34.6 ± 7.1 76.8 ± 15.7 6.3 ± 0.3
A243G 177 ± 10 1024 ± 81 28 ± 1 9.2 ± 0.6 132 ± 23 18 ± 2 31.9 ± 4.7 34.1 ± 7.0 5.0 ± 0.1
Table 1. Kinetic parameters of PDXK variant enzyme forms. All values are the average ± standard deviation 
of at least three independent determinations. aDetermined varying the concentration of the related substrate, 
while keeping the other fixed and saturating. bDetermined with ATP as fixed, saturating substrate. Values of kcat 
determined with the vitamer as fixed, saturating substrate were very similar and are not reported for simplicity.
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the causative nature of candidate genetic variants found in patients, or as a means of obtaining functional infor-
mation about novel disease-linked genes.
Here we used Drosophila to validate the effects of four human variants of the pyridoxal kinase encoding gene 
on genome integrity and glucose metabolism. We previously showed that in Drosophila the depletion of this 
enzyme results in CABs which represent the consequence of hyperglycemia, another phenotype also elicited by 
Pdxk depletion. Also in human cells PDXK silencing produces CABs suggesting functional conservation14.
Low PDXK expression levels have been correlated to lung cancer12 and more recently also to insulin resistance 
which leads to type 2 diabetes26. However in literature, no robust data exist that link specific PDXK variants to 
any specific disease, except for a recent work in which two biallelic mutations in PDXK have been associated to 
polyneuropathy27. Conversely, numerous variants (also in homozygous condition) of the PNPO enzyme, which 
acts downstream of PDXK in the salvage pathway, have been associated to epilepsy28. The reason of this difference 
could be that cells with an impaired PNPO function can anyway produce some PLP throughout the conversion 
of PL into PLP mediated by PDXK; in contrast in cells lacking PDXK, phosphorylation of B6 vitamers does not 
occur and PLP is not produced at all. Thus, it is reasonable to expect, also by considering the wide spectrum of 
functions covered by PLP, that severe mutations of the PDXK gene seriously compromise early developmental 
stages causing lethality in the homozygous condition.
Databases contain PDXK variants (from heterozygous carriers), some of which carry changes in amino acid 
positions that are well conserved in Drosophila. Here we used Drosophila to validate the effects of four human var-
iants (D87H, V128I, H246Q reported in the Exome variant server and the novel A243G variant) of the pyridoxal 
kinase encoding gene on genome integrity and glucose metabolism.
We found that none of the human variants expressed in dPdxk1 mutant flies could rescue CABs, differently 
from what observed with the wild type copy of the PDXK human gene14. This finding reinforces the notion 
(suggested by in silico analysis) that the examined variants are loss-of-function alleles. The expression of all these 
variants did not rescue hyperglycemia caused by dPdxk1 mutation nor the accumulation of AGEs that in dPdxk1 
flies is largely responsible for CABs. The impaired rescue of hyperglycemia displayed by the A243G variant is par-
ticularly interesting because it could be considered as a preliminary indication of the association of PDXK gene 
with diabetes that will be investigated in future studies. Though the role of PDXK mutations in diabetes mellitus 
is purely speculative at this stage of our research, nevertheless, based on the effects of PDXK variants on AGEs, we 
favor the idea that pathophysiology of hyperglycemia might be linked to a combination of impaired insulin action 
on target tissues (i.e. insulin resistance) and reduced beta cell function, as it has been hypothesized for mutations 
of APPL1 gene associated to monogenic diabetes29.
The kinetic characterization of the variant enzymes showed that all mutations affected the catalytic activity 
of PDXK, although with different modalities (Table 1). In general, the effect of D87H and V128I mutations are 
more drastic than those of H246Q and A243G, according to the location of the former couple of residues in a 
more critical region of the enzyme. Also, it is worth noting that D87H and V128I behave similarly, and also var-
iants H246Q and A243G display similar biochemical defects, in agreement with the relative proximity of these 
residues. Interestingly, PLP precursors (PL, PM and PN) have different effects on CAB frequency observed upon 
expression of different variants. The results obtained from the in vitro characterization of the enzymes parallel 
this observation, showing that the kinetic parameters of PLP precursors are differently affected by the mutations. 
In particular, the higher KM for PL (about 10-fold than wild type) displayed by D87H explains why this mutant 
protein did not respond to PL. Differently, KM values for PM and PN about 5 times higher than wild type explain 
the rescue observed only at 1 mM concentration.
The very high KM for both ATP and PL found in the V128 mutant protein explains why PL failed to rescue CABs, 
whereas PN and PM reduced CAB frequency but only at the higher concentration. The H246Q variant, whose mutant 
enzyme form has normal kinetic parameters with PN, responds to both concentrations of this vitamer. The same 
mutant, displaying slightly altered kinetic parameters for ATP (when PL is used as substrate) and PM, responded pos-
itively to these precursors but only at the higher concentration. The A243G mutant enzyme displayed kinetic param-
eters very similar to those showed by H246Q. Similarly to H246Q, this variant responded to PL and PM; however, 
0.5 mM PN was unable to reduce CAB frequency. Such different effects of PDXK mutations on the catalytic properties 
of PDXK are very interesting, since they are related to structure-function relationships of the enzyme. However, their 
full understanding is not possible on the basis of the available data and is postponed to future investigations.
PLP treatment of brains from larvae expressing each of the three variants drastically reduced CABs suggesting 
that this molecule can enter brain cells. A similar behavior had been previously observed in brains from either 
dPdxk1 14 and sgllRNAi larvae (sgll is the Drosophila ortholog of PNPO)25. In contrast, literature reports that in 
humans whereas dephosphorylated B6 vitamers can enter cells and pass the blood-brain barrier, PLP needs to be 
dephosphorylated to PL before entering cells3,30. However, there are no data confirming that such a mechanism 
also occurs in flies. Thus, we can assume that at least under our experimental conditions (e.g. an excess of PLP that 
may force the system) PLP can enter cells without being dephosphorylated to PL.
In Drosophila dPdxk1 is a recessive mutation and heterozygotes do not show CABs. We could expect that the 
same is also true in humans; thus, heterozygous carriers of the examined variants should not exhibit CAB pheno-
type. However, there are certain contexts in which PLP levels are low, and reduced functionality of PDXK could 
be particularly critical. For example, it is known that during pregnancy an increased PLP demand to support fetal 
development causes a drastic reduction of PLP levels that in some cases can contribute to gestational diabetes 
onset. Thus, we can envisage that in pregnant women PDXK variants also carried in heterozygous condition could 
be dangerous. Analogously PDXK variants in heterozygous condition could also impact on genome integrity in 
either patients treated with drugs that reduce PLP levels or also in patients affected by pathologies such as celiac 
disease and diabetes which per se decrease PLP levels31–33. Thus, being able to detect PDXK mutations in such 
contexts could preserve genome integrity and, in the future, may pave the way for personalized cares based on B6 
administration.
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Methods
Materials. All reagents and buffers used for protein purification and enzyme assays were from Sigma Aldrich. 
The enzyme PNPOx from E. coli was purified as previously described in Di Salvo et al.34.
Drosophila stocks and crosses. dPdxk1 mutation was previously described in Marzio et al.14. To introduce 
the transgenes carrying the PDXK variants (PDXK VAR) in a mutant dPdxk1 background we crossed PDXKVAR/
CyGFP; MKRS/TM6B females to CyGFP/Sco; dPdxk1/TM6B males.
The progeny of this cross, PDXKVAR /CyGFP; dPdxk1/TM6B, was crossed inter se to obtain a stable stock. From 
this stock larvae PDXKVAR; dPdxk1/ dPdxk1 selected for their non-Tubby phenotype have been analyzed. To test 
PDXKVAR on a dPdxk1/+ background we analyzed larvae PDXKVAR/Cy; dPdxk1/TM6B from the same stock.
The Oregon R strain was used as wild-type control. All stocks were maintained and crosses were made at 25 °C 
on standard Drosophila medium (prepared from cornmeal, sucrose, brewer’s yeast, agar, water and treated with 
propionic acid) or on a supplemented medium (see below). The balancers and the genetic markers used in these 
crosses are described in detail in FlyBase (http://flybase.bio.indiana.edu/).
Site directed mutagenesis. D87H, V128I, H246Q and A243G PDXK variants were generated by intro-
ducing mutations (by PCR based site-directed mutagenesis, QuikChange II XL Site-Directed Mutagenesis Kit, 
Agilent) into the wild type HA-tagged PDXK gene.
Primers used are:
D87H A gccaggaacgacttgtgcctcgtataacctgtg
D87H B cacaggttatacgaggcacaagtcgttcctggc
V128I A gcgaaggctcgatgtacatcccggaggacc
V128I B ggtcctccgggatgtacatcgagccttcgc
H246Q A gttattggggtgcttctgtgtccacgccagg
H246Q B cctggcgtggacacagaagcaccccaataac
A234G A cttgtgtgtccaccccaggagcatggc
A243G B gccatgctcctggggtggacacacaag
PDXK genes carrying the mutations were then cloned into a pCaSpeR-tubulin vector35. The correct generation 
of the variants was verified by Sanger sequencing and recombinant plasmids were introduced in flies by germline 
transformation (Best Gene Inc. Service, USA).
chromosome cytology. Colchicine-treated Drosophila metaphase chromosome preparations for CAB 
scoring were obtained as previously described in Gatti and Goldberg and in Merigliano et al.24,36,37. Anti-AGEs 
immunostaining of brain preparations from third instar larvae was carried out according to Bonaccorsi et al.38. 
Preparations were rinsed in PBS 0.1% Triton (PBST), incubated overnight at 4 °C with rabbit anti-human AGE 
antibody (1:200 in PBST; ab23722, Abcam,UK), rinsed in PBST, and then incubated for 1 hr at room temperature 
with the secondary antibody (Alexa-Fluor-555-conjugated anti-rabbit antibody 1:300 in PBST; Molecular Probes, 
Eugene, OR). All fixed preparations were mounted in Vectashield H-1200 with 4,6 diamidino-2-phenylindole 
(DAPI) (Vector Laboratories, Burlingame, CA) to stain the DNA. To quantify cells positive to AGE immunos-
taining at least 1000 cells were analyzed for each genotype. All cytological preparations were examined with a Carl 
Zeiss (Thornwood, NY) Axioplan fluorescence microscope, equipped with an HBO100W mercury lamp and a 
cooled charged-coupled device (CCD camera; Photometrics CoolSnap HQ).
treatments of larvae and isolated brains. To test the effects of PLP and PLP precursors on CABs, brains 
were dissected from third instar larvae and incubated for 4 hours in 2 ml of saline supplemented with 10% fetal 
bovine serum (FBS, Corning) with addition of 0.5 or 1 mM PLP, PM, PL or PN. 1 h before fixation brains were 
treated with colchicine 10−2 M (final concentration). To test the effects of glucose on AGE frequency brains 
were dissected from third instar larvae and incubated in 2 ml of saline supplemented with 10% fetal bovine 
serum (FBS, Corning) for 4 hours with addition of 1% glucose. Then, brains were treated according to the above 
described procedure for immunostaining. To test the effect of PLP on glucose content we reared flies in standard 
medium supplemented with PLP 1 mM. About 5 days later larvae were dissected to extract hemolymph and to 
measure glucose content (see paragraph below).
Glucose measurement. Glucose concentration in hemolymph from third instar larvae was measured using 
the Infinity Glucose Hexokinase reagent (Thermo scientific). Hemolymph collection and glucose measurement 
were done as described in Marzio et al.14.
Western blotting. Extracts for Western blotting were prepared by lysing samples of 20 brains in 150 mM 
NaCl, 50 mM Tris-HCl, pH 7.5, 30 mM NaF, 25 mM b-glycerophosphate, 0.2 mM Na3VO4, Triton X-100 1%, 
and complete Protease Inhibitor Cocktail (Roche). Extracts were immunoblotted according to Somma et al.39; 
blotted proteins were detected using an antibody against HA tag (Anti-HA-Peroxidase 12013819001 Roche). 
Anti-alpha tubulin (SIGMA) was used as loading control. Primary antibodies were detected using HRP conju-
gated anti-mouse and anti-rabbit IgGs and the ECL detection kit (all from GE Healthcare). Chemiluminescent 
blots were imaged with the ChemiDoc MP imager (Bio-Rad). Band intensities were quantified by densitometric 
analysis with Image Lab software (Bio-Rad).
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Production, purification and in vitro characterization of pDXK variant enzyme forms. Variant 
PDXK genes were cloned into the pET 28b(+) expression vector and this was transformed into E. coli Rosetta 
(λDE3) pLysS competent cells for protein expression. Purification of proteins was carried out as previously 
described in Musayev et al.19. Enzyme activity was assayed with PL and ATP (sodium salt) as substrates, using 
1 µM enzyme, and were performed in a 1 cm thermostated cuvette in 100 mM NaBES buffer pH 7.3, contain-
ing 100 mM MgCl2, at 37 °C. The conversion of PL into PLP was followed at 388 nm as previously described 
in Musayev et al.19, in an Agilent 8454 UV/Vis diode array spectrophotometer. An extinction coefficient of 
4900 cm−1 M−1 was used to calculate the concentration of the PLP product. Enzyme activity with PN and PM as 
substrates was measured in a spectrophotometric coupled assay, in which the phosphorylated products generated 
by PDXK were converted into PLP by E. coli PNPOx. The assay was carried out in the same conditions described 
above, with either 0.1 µM PDXK and 1 µM PNPOx (when using PN) or 0.05 µM PDXK and 5 µM PNPOx (when 
using PM). For each PDXK variant form, two series of initial velocity measurements were carried out, varying the 
concentration of one substrate while keeping the concentration of the other fixed and saturating. The obtained 
saturation curves were fitted to the Michaelis-Menten equation, using the software PRISM (GraphPad, La Jolla, 
CA, USA), obtaining estimates of the kinetic parameters.
Statistical analysis. Results are expressed as means ± SD; probability values < 0.05 were considered statisti-
cally significant. Statistical analysis of the data was done with the two-tailed Student’s t-test.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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